Find a Cancer Program  Log in to MyNetwork
Facebook  LinkedIn  Twitter  ACCC Youtube Channel

Search Drug Alphabetically

Generic Name BCG live intravesical vaccine
Brand Name TICE® BCG
Payment Category Medicare Part B
Year Introduced 1990
Type of Drug Attenuated, live culture preparation
HCPCS J9030
Billing Unit 1 mg
Medicare Payment Limit (Effective January 1, 2021) $2.85

FDA-Approved Indication(s)

  • Indicated for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder, and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection.

Approved Indication(s) with Orphan Drug Status None
ICD-10 Code(s) for Labeled Indication(s) Carcinoma in situ of bladder [D09.0]
Name Strength Form Package Labeler NDC

Copyright © 2021 Association of Community Cancer Centers. All Rights Reserved.
11600 Nebel Street, Suite 201, Rockville, MD 20852  |  Tel.: 301.984.9496  |  Fax: 301.770.1949

CONTACT US